Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome.

ABSTRACT:

Purpose

Understanding the molecular mediators of breast cancer survival is critical for accurate disease prognosis and improving therapies. Here, we identified Neuronatin (NNAT) as a novel antiproliferative modifier of estrogen receptor-alpha (ER+) breast cancer.

Experimental design

Genomic regions harboring breast cancer modifiers were identified by congenic mapping in a rat model of carcinogen-induced mammary cancer. Tumors from susceptible and resistant congenics were analyzed by RNAseq to identify candidate genes. Candidates were prioritized by correlation with outcome, using a consensus of three breast cancer patient cohorts. NNAT was transgenically expressed in ER+ breast cancer lines (T47D and ZR75), followed by transcriptomic and phenotypic characterization.

Resul

SUBMITTER: Plasterer C 

PROVIDER: S-EPMC10317546 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature